Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group.
Brandão M, Prisciandaro E, Xenophontos E, Mariolo A, Sadeghi AH, Filippi AR, Levy A, Bandura A, Caramella C, Dickhoff C, de Margerie-Mellon C, Faivre-Finn C, Portik D, Sanchez-Lorente D, De Ruysscher D, Smit E, Gobbini E, Fadel E, Ruffini E, Olmetto E, Cortiula F, Bahce I, Houda I, Opitz I, Naidoo J, Edwards J, Remon J, Benitez JC, Trujillo JC, Derks J, Amrane K, Hartemink KJ, Stathopoulos K, Hendriks LEL, Iglesias M, Occhipinti M, Guckenberger M, Giaj Levra N, Girard N, Reguart N, Mercier O, Bironzo P, Hofman P, Petersen RH, De Angelis R, Abgral R, Terrisse S, Popat S, Pierret T, Blum TG, Ricardi U, Dionisi V, Berghmans T, Dingemans AC; European Organisation for Research, Treatment of Cancer EORTC Lung Cancer Group.
Brandão M, et al.
Lung Cancer. 2025 Nov;209:108798. doi: 10.1016/j.lungcan.2025.108798. Epub 2025 Oct 14.
Lung Cancer. 2025.
PMID: 41108881
The MDT determined the resectability of each tumor, and non-consensual cases underwent a second and a third discussion rounds. A TNM-subset was classified as "resectable" if 75 % of cases within that category were deemed "resectable" following multiple rounds of rev …
The MDT determined the resectability of each tumor, and non-consensual cases underwent a second and a third discussion rounds. A TNM- …